Award
National Cancer Institute 2R44CA277917-02
Targeting pancreatic cancer metastases with Targefrin
Recipient
ARMIDA LABS, INC.
Award Amount
$1,162,000.00
Ceiling
$1,162,000.00
Awarded
September 10, 2025
Identifier
2R44CA277917-02
NIH awarded ARMIDA LABS, INC. a Phase II SBIR grant to develop Targefrin-dimer, a therapeutic agent targeting EphA2 to inhibit pancreatic cancer metastases, with a total award amount of $1,162,000.
Description
This NIH SBIR Phase II grant opportunity focuses on developing a therapeutic agent targeting EphA2 for pancreatic cancer metastasis. The project involves manufacturing, IND-enabling studies, and clinical trials.